Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| California Walnut Commission | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to examine the impact of daily consumption of walnuts for 12 weeks on cognitive function, markers of inflammation and oxidative stress, and the gut microbiome in healthy adults age 55 years and older.
The investigators will determine the extent to which daily consumption of walnuts by older adults for 12 weeks influences cognitive function and whether improvements are associated with changes in the resident gut microbiota. The investigators propose that age-related cognitive decline can be mitigated by consuming walnuts, by modulating the microbiota and microbial metabolites and decreasing oxidative stress and inflammation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Walnuts | Active Comparator | Daily consumption of 1.5 ounces (42.5 g) of plain walnuts for 12 weeks |
|
| Crackers | Placebo Comparator | Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Walnuts | Other | Daily consumption of 1.5 ounces of plain walnuts for 12 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive function - memory | Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome) | 0 and 12 weeks |
| Cognitive function - memory | Change from baseline at week 12: proximity (lower score reflects positive outcome) | 0 and 12 weeks |
| Cognitive function - cognitive flexibility | Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome) | 0 and 12 weeks |
| Cognitive function - cognitive flexibility | Change from baseline at week 12: proximity (lower score reflects positive outcome) | 0 and 12 weeks |
| Cognitive function - speed of processing | Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome) | 0 and 12 weeks |
| Gut microbiome composition | Change from baseline at week 12: microbiome composition | 0 and 12 weeks |
| Lipid oxidation levels | Change from baseline at week 12: plasma malondialdehyde (MDA) | 0 and 12 weeks |
| Gut permeability and health: Inflammatory biomarkers |
| Measure | Description | Time Frame |
|---|---|---|
| Urolithin concentrations | Change from baseline at week 12: urolithin A and urolithin B concentrations in urine | 0 and 12 weeks |
| Blood pressure | Change from baseline at week 12: systolic and diastolic blood pressure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Emily Ho, PhD | Contact | 541-737-9559 | emily.ho@oregonstate.edu | |
| Sandra Uesugi, RN, BSN, MS | Contact | 541-737-3594 | sandra.uesugi@oregonstate.edu |
| Name | Affiliation | Role |
|---|---|---|
| Emily Ho, PhD | Oregon State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon State University | Recruiting | Corvallis | Oregon | 97331 | United States |
Not provided
| Label | URL |
|---|---|
| This website provides detailed study information for potential participants as well as an online screening survey to assess potential eligibility. Additionally, 2 in-person screening visits follow the online screening survey to assess eligibility. | View source |
Not provided
Individual participant data will not be shared with other researchers without IRB approval.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study staff performing cognitive tests and analyzing samples and cognitive data will be blinded.
| Crackers |
| Other |
Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts) |
|
Change from baseline at week 12: Gut inflammatory biomarkers fecal calprotectin and myeloperoxidase |
| 0 and 12 weeks |
| Biomarkers of inflammation | Change from baseline at week 12: Plasma inflammatory markers (ex. CRP and IL-6) | 0 and 12 weeks |
| 0 and 12 weeks |
| Weight | Change from baseline at week 12: weight | 0 and 12 weeks |